Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexuprazan in Gastric Ulcer
NCT07730138Phase 3Not yet recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Oct 2026
- Primary completion
- Apr 2028
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of fexuprazan in gastric ulcer (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoint: Cumulative gastric ulcer healing rate at 8 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
fexuprazan
03
Conditions
gastric ulcer
Beyond the preview
Go deeper on NCT07730138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07730138.